Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472350 | 1.00 | AHR (0.35) | AHRMAPK1FLT1HPGDTSHR | |
| SCHEMBL9396186 | 0.88 | MAPK1 (0.38) | AHRMAPK1FLT1HPGDTSHR | |
| SCHEMBL9292254 | 0.87 | ALOX15 (0.36) | MAPK1ALOX15ALOX12IDO1CYP3A4 | |
| SCHEMBL3875287 | 0.81 | GPR84 (0.38) | CYP3A4 | |
| SCHEMBL12659938 | 0.81 | CD44 (0.42) | HSD17B10ALOX15ALOX12CYP3A4 | |
| SCHEMBL23214736 | 0.81 | HSD17B10 (0.48) | MAPK1HPGDTSHRHSD17B10ALOX15 | |
| SCHEMBL338590 | 0.78 | TRPA1 (0.32) | TSHR | |
| SCHEMBL383208 | 0.75 | TAAR1 (0.53) | MAPK1TSHRCYP3A4 | |
| SCHEMBL6943976 | 0.75 | TRPV4 (0.36) | MAPK1 | |
| SCHEMBL23214719 | 0.75 | TAAR1 (0.48) | TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4527868-A2 | COMPOUND AND POLYMERIC COMPOUND INCLUDING SAID COMPOUND | Japan Science and Technology Agency (JP) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-12145938-B2 | Compound and polymer compound containing the compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-11-19 | — | — | US | disclosed |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11963967-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| EP-0634401-B1 | MDR reversal agents | AMERICAN CYANAMID CO (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5639887-A | MULTIDRUG RESISTANT CELLS; INCREASE CELL SENSITIVITY TO ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | AHR 44/4885MAPK1 1048/4885FLT1 1891/4885 |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | RAD51, MDM2, UBE2D3 | AHR 955/4885MAPK1 3098/4885FLT1 368/4885 |
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | AHR 4323/4885MAPK1 2927/4885FLT1 3829/4885 |
| US-12145938-B2 | Compound and polymer compound containing the compound | RAD51, MDM2, UBE2D3 | AHR 955/4885MAPK1 3098/4885FLT1 368/4885 |
| US-11963967-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | AHR 3531/4885MAPK1 4211/4885FLT1 4836/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | AHR 44/4885MAPK1 1048/4885FLT1 1891/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | AHR 1857/4885MAPK1 2579/4885FLT1 4632/4885 |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | AHR 1016/4885MAPK1 1056/4885FLT1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.